El C3b del complemento contribuye a la agregación plaquetaria inducida por Escherichia coli en sangre total humana

INTRODUCTION: Platelets have essential functions as first responders in the immune response to pathogens. Activation and aggregation of platelets in bacterial infections can lead to life-threatening conditions such as arterial thromboembolism or sepsis-associated coagulopathy. METHODS: In this study, we investigated the role of complement in Escherichia coli (E. coli)-induced platelet aggregation in human whole blood, using Multiplate® aggregometry, flow cytometry, and confocal microscopy. RESULTS AND DISCUSSION: We found that compstatin, which inhibits the cleavage of complement component C3 to its components C3a and C3b, reduced the E. coli-induced platelet aggregation by 42%-76% (p = 0.0417). This C3-dependent aggregation was not C3a-mediated as neither inhibition of C3a using a blocking antibody or a C3a receptor antagonist, nor the addition of purified C3a had any effects. In contrast, a C3b-blocking antibody significantly reduced the E. coli-induced platelet aggregation by 67% (p = 0.0133). We could not detect opsonized C3b on platelets, indicating that the effect of C3 was not dependent on C3b-fragment deposition on platelets. Indeed, inhibition of glycoprotein IIb/IIIa (GPIIb/IIIa) and complement receptor 1 (CR1) showed that these receptors were involved in platelet aggregation. Furthermore, aggregation was more pronounced in hirudin whole blood than in hirudin platelet-rich plasma, indicating that E. coli-induced platelet aggregation involved other blood cells. In conclusion, the E. coli-induced platelet aggregation in human whole blood is partly C3b-dependent, and GPIIb/IIIa and CR1 are also involved in this process.

Resumen tomado de PubMed (NCBI) para el registro citado, en el idioma original. La versión de referencia es la de la publicación original.

El resumen se deja sin traducir para conservar la redacción original de los autores.

En sangre total humana con hirudina se examinó la contribución del complemento a la agregación plaquetaria inducida por Escherichia coli. Compstatina, que bloquea la escisión de C3, la redujo un 42 %-76 % (p = 0,0417), y un anticuerpo anti-C3b un 67 % (p = 0,0133); inhibir o añadir C3a no tuvo efecto. No se detectó C3b opsonizado en plaquetas; participaron GPIIb/IIIa y CR1. Los autores concluyen que la agregación es parcialmente C3b-dependiente e involucra otras células sanguíneas.

Explore cómo esta investigación se conecta con la práctica clínica

Más estudios revisados por pares en la categoría «Resistencia antimicrobiana».

• Novel Leech Antimicrobial Peptides — Hirunipins — Kumar et al. (2025)
• Péptidos antimicrobianos derivados de neuropéptidos de invertebrados para aplicaciones biomédicas — Salzet M et al. (2005)
• El microbioma de Hirudo medicinalis es una fuente de nuevos péptidos antimicrobianos — Grafskaia E et al. (2020)
• Los antimicrobianos a bajas concentraciones en la sanguijuela medicinal seleccionan patógenos resistentes que se transmiten a los pacientes — Beka L et al. (2018)
• Actividad antibacteriana no glicosidasa de la destabilasa-lisozima de invertebrados y de sus péptidos anfipáticos helicoidales — Zavalova LL et al. (2006)
• Identificación y clonación de una lisozima de tipo invertebrado a partir de Eisenia andrei — Josková R et al. (2009)
• Lecciones neuroinmunitarias de un anélido: la sanguijuela medicinal — Tasiemski A, Salzet M (2017)
• Papel de los péptidos antimicrobianos en la inmunidad de las sanguijuelas parásitas — Kaygorodova IA (2023)
• Clinical Efficacy of Leech Therapy (Ta'līq al-'Alaq) in Eczema (Nār Fārsī): An Open-Label Single-Arm Clinical Study — Ulla P BS et al. (2025)
• El inhibidor de la elastasa eglina no tiene efecto en un modelo ovino de endotoxemia — Redl H et al. (1988)

Ver toda la investigación analizada por la ASH →